Epirubicin (E) followed by cyclophosphamide, methotrexate, 5-fluorouracil (CMF) versus paclitaxel (T) followed by epirubicin and vinorelbine (EV) in patients (pts) with high-risk operable breast cancer

被引：0
|
作者：
Boccardo, F. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Rubagotti, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Guglielmini, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Sismondi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Farris, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Amadori, D. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Agostara, B. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Gambi, A. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Catalano, G. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
Faedi, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ]
机构：
[1] Univ Genoa, Natl Inst Canc Res, Genoa, Italy
[2] Univ Mauriziano, Molinette Mauriziano Hosp, Turin, Italy
[3] Univ Sassari, I-07100 Sassari, Italy
[4] Tumor Inst Meldola, Forli, Italy
[5] M Ascoli Hosp, Palermo, Italy
[6] Infermi Hosp, Faenza, Italy
[7] Gen Hosp Pesaro, Pesaro, Italy
[8] Osped Gen Provinciale M Bufalini, Cesena, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11521
引用
收藏
页数：2
相关论文
共 50 条
  • [1] EPIRUBICIN (E) FOLLOWED BY CYCLOPHOSPHAMIDE, METHOTREXATE AND 5-FLUOROURACIL (CMF) VERSUS PACLITAXEL (T) FOLLOWED BY EPIRUBICIN AND VINORELBINE (EV) IN PATIENTS WITH HIGH-RISK OPERABLE BREAST CANCER
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Amadori, Dino
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    Boccardo, Francesco
    ANNALS OF ONCOLOGY, 2009, 20
  • [2] Epirubicin Followed by Cyclophosphamide, Methotrexate and 5-Fluorouracil versus Paclitaxel Followed by Epirubicin and Vinorelbine in Patients with High-Risk Operable Breast Cancer
    Boccardo, Francesco
    Amadori, Dino
    Guglielmini, Pamela
    Sismondi, Piero
    Farris, Antonio
    Agostara, Biagio
    Gambi, Angelo
    Catalano, Giuseppina
    Faedi, Marina
    Rubagotti, Alessandra
    ONCOLOGY, 2010, 78 (3-4) : 274 - 281
  • [3] Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer
    Burnell, Margot
    Levine, Mark N.
    Chapman, Judith-Anne W.
    Bramwell, Vivien
    Gelmon, Karen
    Walley, Barbara
    Vandenberg, Ted
    Chalchal, Haji
    Albain, Kathy S.
    Perez, Edith A.
    Rugo, Hope
    Pritchard, Kathleen
    O'Brien, Patti
    Shepherd, Lois E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (01) : 77 - 82
  • [4] Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer
    Dino Amadori
    Rosella Silvestrini
    Mario De Lena
    Francesco Boccardo
    Andrea Rocca
    Emanuela Scarpi
    Francesco Schittulli
    Mario Brandi
    Roberta Maltoni
    Patrizia Serra
    Riccardo Ponzone
    Nicoletta Biglia
    Lorenzo Gianni
    Amelia Tienghi
    Maria Rosaria Valerio
    Paola Bonginelli
    Laura Amaducci
    Marina Faedi
    Editta Baldini
    Angelo Paradiso
    Breast Cancer Research and Treatment, 2011, 125 : 775 - 784
  • [5] Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer
    Amadori, Dino
    Silvestrini, Rosella
    De Lena, Mario
    Boccardo, Francesco
    Rocca, Andrea
    Scarpi, Emanuela
    Schittulli, Francesco
    Brandi, Mario
    Maltoni, Roberta
    Serra, Patrizia
    Ponzone, Riccardo
    Biglia, Nicoletta
    Gianni, Lorenzo
    Tienghi, Amelia
    Valerio, Maria Rosaria
    Bonginelli, Paola
    Amaducci, Laura
    Faedi, Marina
    Baldini, Editta
    Paradiso, Angelo
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (03) : 775 - 784
  • [6] Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes
    Battelli, Nicola
    Massacesi, Cristian
    Braconi, Chiara
    Pilone, Alberta
    Manzione, Luigi
    Dinota, Angelo
    Cobelli, Stefano
    Scanni, Alberto
    Sturba, Fabio
    Giacomini, Giusi
    Morale, Donatella
    Giorgi, Francesca
    Tummarello, Diego
    Cascinu, Stefano
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (04): : 380 - 384
  • [7] Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma
    Cocconi, G
    Di Blasio, B
    Boni, C
    Bisagni, G
    Ceci, G
    Rondini, E
    Bella, M
    Leonardi, F
    Savoldi, L
    Camisa, R
    Bruzzi, P
    CANCER, 2002, 95 (02) : 228 - 235
  • [8] Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer
    Papadimitriou, CA
    Dimopoulos, MA
    Ampela, C
    Louvrou-Fertaki, A
    Anagnostopoulos, A
    Athanassiades, P
    Stamatelopoulos, S
    Keramopoulos, A
    ONCOLOGY, 1998, 55 (06) : 533 - 537
  • [9] Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide
    Kim, Seung Jin
    Taguchi, Tetsuya
    Shimazu, Kenzo
    Tanji, Yoshio
    Tamaki, Yasuhiro
    Noguchi, Shinzaburo
    ONCOLOGY, 2009, 77 (02) : 134 - 139
  • [10] Postoperative dose-dense sequential chemotherapy with Epirubicin (E) followed by CMF with or without Paclitaxel (P) in patients with high-risk breast cancer
    Fountzilas, George
    Skarlos, Dimosthenis
    Gogas, Helen
    Briasoulis, Evangeios
    Papadimitriou, Christos
    Polichronis, Athanassios
    Farfarelos, Christos
    Xepapadakis, Grigoris
    Abela, Konstantina
    Aravantinos, Gerassismos
    ANNALS OF ONCOLOGY, 2004, 15 : 55 - 55
12345